Skip to main content

Advertisement

SpringerLink
Log in

Proteinuria in diabetic nephropathy: Treatment and evolution

  • Published:
Current Diabetes Reports Aims and scope Submit manuscript

Abstract

Diabetic nephropathy is characterized by increased urinary albumin excretion and loss of renal function. Increased urinary albumin (proteinuria) is a key component of this disease. Previously, its development led to end-stage renal disease with increased mortality and morbidity for diabetic patients versus nondiabetic patients. Several treatment strategies currently exist that can prevent, slow, and even reverse diabetic nephropathy. New trials suggest that a multidisciplinary approach focused on optimizing metabolic and hypertensive control, in addition to the use of angiotensin-converting enzyme inhibitors or angiotensin 2 receptor antagonists, is effective in halting the progression of disease. Screening and implementation of these strategies is needed to reverse the epidemic of diabetic renal disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. US Renal Data System: USRDS 2000 Annual Data Report. Bethesda, MD: The National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2000.

  2. Collins A, Xue J, Ma J, Louis T: Estimating the number of patients and Medicare costs for end stage renal disease in the US to the year 2010. J Am Soc Nephrol 2000, 11:113A.

    Google Scholar 

  3. International Diabetes Federation and International Society of Nephrology Booklet: Diabetes and Kidney Disease, "Time to Act." Brussels: International Diabetes Federation and International Society of Nephrology; 2003.

  4. Pugh J, Medina R, Cornell J, Basu S: NIDDM is the major cause of diabetic end-stage renal disease. More evidence from a triethnic community. Diabetes 1995, 44:1375–1380.

    Article  PubMed  CAS  Google Scholar 

  5. Seaquist E, Goetz F, Rich S, Barbosa J: Familial clustering of diabetic kidney disease; evidence for genetic susceptibility to diabetic nephropathy. N Engl J Med 1989, 320:1161–1165.

    Article  PubMed  CAS  Google Scholar 

  6. Parving H:Diabetic nephropathy: prevention and treatment. Kidney Int 2001, 60:2041–2055. A review of the pathogenesis, progression, and treatment of type 1 and type 2 diabetic nephropathy.

    Article  PubMed  CAS  Google Scholar 

  7. Ruggenenti P, Perna A, Mosconi L, et al.: Urinary protein excretion rate is the best independent predictor of ESRF in non-diabetic proteinuric chronic nephropathies. Kidney Int 1998, 53:1209–1216.

    Article  PubMed  CAS  Google Scholar 

  8. Ismail N, Becker B, Strzelczyk P, Ritz E: Renal disease and hypertension in non-insulin-dependent diabetes mellitus. Kidney Int 1999, 55:1–28.

    Article  PubMed  CAS  Google Scholar 

  9. Lewis E, Hunsicker L, Bain R, Rohde R: The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 1993, 239:1456–1462.

    Article  Google Scholar 

  10. Wilmer W, Hebert L, Lewis E, et al.: Remission of nephrotic syndrome in type 1 diabetes: long-term follow-up of patients in the Captopril Study. Am J Kidney Dis 1999, 34:308–314.

    PubMed  CAS  Google Scholar 

  11. Dunn B, Zatz R, Rennke H, et al.: Prevention of glomerular capillary hypertension in experimental diabetes mellitus obviates functional and structural glomerular injury. J Hypertens Suppl 1986, 4:S251-S254.

    PubMed  CAS  Google Scholar 

  12. Morgensen C: Early glomerular hyperfiltration in insulindependent diabetics and late nephropathy. Scand J Clin Lab Invest 1986, 46:201–206.

    Google Scholar 

  13. Gragnoli G, Signorini S, Tanganelli I, et al.: Prevalence of glomerular hyperfiltration and nephromegaly in normo- and microabluminuric type 2 diabetic patients. Nephron 1993, 65:206–211.

    PubMed  CAS  Google Scholar 

  14. Vedel P, Obel J, Nielsen F, et al.: Glomerular hyperfiltration in microalbuminuric NIDDM patients. Diabetologia 1996, 39:1584–1589.

    Article  PubMed  CAS  Google Scholar 

  15. Hostetter T, Rennke H, Brenner B: The case for intrarenal hypertension in the initiation and progression of diabetic and other glomerulopathies. Am J Med 1982, 72:375–380.

    Article  PubMed  CAS  Google Scholar 

  16. Lee H, Yu M, Yang Y, et al.: Reactive oxygen species-regulated signaling pathways in diabetic nephropathy. J Am Soc Nephrol 2003, 14:S241-S245.

    Article  PubMed  CAS  Google Scholar 

  17. Kelly D, Zhang Y, Hepper C, et al.: Protein kinase C beta inhibition attenuates the progression of experimental diabetic nephropathy in the presence of continued hypertension. Diabetes 2003, 52:512–518.

    Article  PubMed  CAS  Google Scholar 

  18. Forbes J, Cooper M, Oldfield M, Thomas M: Role of advanced glycation end products in diabetic nephropathy. J Am Soc Nephrol 2003, 14:S254-S258.

    Article  PubMed  CAS  Google Scholar 

  19. Edelstein K, Brownlee M: Aminoguanidine ameliorates albuminuria in diabetic hypertensive rats. Diabetologia 1992, 35:96–97.

    Article  PubMed  CAS  Google Scholar 

  20. Soulis-Liparota T, Cooper M, Papazoglou D, et al.: Retardation by aminoguanidine of development of albuminuria, mesangial expansion, and tissue fluorescence in streptozotocin-induced diabetic rats. Diabetes 1991, 40:1328–1334.

    Article  PubMed  CAS  Google Scholar 

  21. Wang S, LaPage J, Hirschberg R: Role of glomerular ultrafiltration of growth factors in progressive interstitial fibrosis in diabetic nephropathy. Kidney Int 2000, 57:1002–1012.

    Article  PubMed  CAS  Google Scholar 

  22. Amann B, Tinzmann R, Angelkort B: ACE inhibitors improve diabetic nephropathy through suppression of renal MCP-1. Diabetes Care 2003, 8:2421–2425.

    Article  Google Scholar 

  23. Sharma K, Ziyadeh F: Hyperglycemia and diabetic kidney disease. The case for transforming growth factor-beta as a key mediator. Diabetes 1995, 44:1139–1146.

    Article  PubMed  CAS  Google Scholar 

  24. Benigni A, Zoja C, Corna D, et al.: Add-on anti-TGF beta antibody in ACE inhibitor arrests progressive diabetic nephropathy in the rat. J Am Soc Nephrol 2003, 14:1816–1824.

    Article  PubMed  CAS  Google Scholar 

  25. Remuzzi G, Bertani T: Pathophysiology of progressive nephropathies. N Engl J Med 1998, 339:1448–1456. A review of the molecular effects of proteinuria on interstitial fibrosis and loss of renal function.

    Article  PubMed  CAS  Google Scholar 

  26. Bohle A, Wehrmann M, Bogenschutz O, et al.: The pathogenesis of chronic renal failure in diabetic nephropathy. Investigation of 488 cases of diabetic glomerulosclerosis. Pathol Res Pract 1991, 187:251–259.

    PubMed  CAS  Google Scholar 

  27. Bertani T, Zoja C, Abbate M, et al.: Age-related nephropathy and proteinuria in rats with intact kidney exposed to diets with different protein options. Lab Invest 1989, 60:196–204.

    PubMed  CAS  Google Scholar 

  28. Wang S, LaPage J, Hirschberg R: Role of glomerular ultrafiltration of growth factors in progressive interstitial fibrosis in diabetic nephropathy. Kidney Int 2000, 57:1002–1014.

    Article  PubMed  CAS  Google Scholar 

  29. Zoja C, Morigi M, Figliuzzi M: Proximal tubular cell synthesis and secretion of endothelin-1 on challenge with albumin and other proteins. Am J Kid Dis 1995, 26:934–941.

    PubMed  CAS  Google Scholar 

  30. Abbate M, Benigni A, Bertani T, Remuzzi G: Nephrotoxicity of increased glomerular protein traffic. Nephrol Dial Transplant 1999, 14:304–312.

    Article  PubMed  CAS  Google Scholar 

  31. Effects of ramipril on cardiovascular and micorvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. The HOPE Investigators [no authors listed]. Lancet 2000, 355:253–259.

  32. Lindholm L, Ibsen H, Borch-Johnsen K, et al.: Risk of new-onset diabetes in the Losartan Intervention for Endpoint reduction in hypertension study. J Hypertens 2002, 20:1879–1886.

    Article  PubMed  CAS  Google Scholar 

  33. Hovind P, Rossing P, Tarnow L, et al.: Remission of nephroticrange albuminuria in type 1 diabetic patients. Diabetes Care 2001, 24:1972–1977.

    Article  PubMed  CAS  Google Scholar 

  34. Gall M, Nielsen F, Smitz U, Parving H: The course of kidney function in type 2 (non-insulin-dependent) diabetic patients with diabetic nephropathy. Diabetologia 1993, 36:1071–1078.

    Article  PubMed  CAS  Google Scholar 

  35. Lewis J, Berl T, Bain R, et al.: Effect of intensive blood pressure control on the course of type 1 diabetic nephropathy. Am J Kidney Dis 1999, 334:809–817.

    Google Scholar 

  36. Bakris G, Weir M, Shanifar S, et al.: Effects of blood pressure level on progression of diabetic nephropathy. Arch Intern Med 2003, 163:1555–1565.

    Article  PubMed  Google Scholar 

  37. Bakris G, Williams M, Dworkin L, et al.: Preserving renal function in adults with hypertension and diabetes: a consensus approach. Am J Kidney Dis 2000, 36:646–661.

    PubMed  CAS  Google Scholar 

  38. Hovind P, Rossing P, Tarnow L, et al.: Remission and regression in the nephropathy of type 1 diabetes when blood pressure is controlled aggressively. Kidney Int 2001, 60:277–283.

    Article  PubMed  CAS  Google Scholar 

  39. Chobanian A, Bakris G, Black H, et al.: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003, 9:2560–2572.

    Article  Google Scholar 

  40. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39 [no authors listed]. BMJ 1998, 317:713–720.

  41. Lewis E, Hunsicker L, Clarke W, et al.: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001, 345:851–860.

    Article  PubMed  CAS  Google Scholar 

  42. Brenner B, Cooper M, Zeeuw DD, et al.: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001, 345:861–869.

    Article  PubMed  CAS  Google Scholar 

  43. Lapinski R, Perico N, Remuzzi A, et al.: Angiotensin II modulates glomerular capillary permselectivity in rat isolated perfused kidney. J Am Soc Nephrol 1996, 7:653–660.

    PubMed  CAS  Google Scholar 

  44. Kelly D, Aaltonen P, Cox A, et al.: Expression of the slitdiaphragm protein, nephrin, in experimental diabetic nephropathy: differing effects of anti-proteinuric therapies. Nephrol Dial Transplant 2002, 17:1327–1332.

    Article  PubMed  CAS  Google Scholar 

  45. Should all patients with type 1 diabetes mellitus and microalbuminuria receive angiotensin-converting enzyme inhibitors? A meta-analysis of individual patient data. ACE Inhibitors in Diabetic Nephropathy Trialist Group [no authors listed]. Ann Intern Med 2001, 134:370–379.

  46. Ravid M, Brosh D, Levi Z, et al.: Use of enalapril to attenuate decline in renal function in normotensive, normoalbuminuric patients with type 2 diabetes mellitus. A randomized, controlled trial. Ann Intern Med 1998, 128:982–988.

    PubMed  CAS  Google Scholar 

  47. Ruggenenti P, Mosconi L, Sangalli F, et al.: Glomerular sizeselectivity dysfunction in NIDDM is not ameliorated by ACE inhibition of by calcium channel blockade. Kidney Int 1999, 55:984–994.

    Article  PubMed  CAS  Google Scholar 

  48. Parving H, Hovind P, Rossing K, Andersen S: Evolving strategies for renoprotection: diabetic nephropathy. Curr Opin Nephrol Hypertens 2001, 10:515–522.

    Article  PubMed  CAS  Google Scholar 

  49. Parving P, Lehnert H, Brochner-Mortensen J, et al.: The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001, 345:870–878.

    Article  PubMed  CAS  Google Scholar 

  50. Mann J, Gerstein H, Pogue J, et al.: Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Intern Med 2001, 134:629–636.

    PubMed  CAS  Google Scholar 

  51. Dahlof B, Devereux R, Kjeldsen S, et al.: Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002, 359:995–1003.

    Article  PubMed  CAS  Google Scholar 

  52. Campbell R, Sangalli F, Perticucci E, et al.: Effects of combined ACE inhibitor therapy and angiotensin II antagonist treatment in chronic nephropathies. Kidney Int 2003, 63:1094–1103.

    Article  PubMed  CAS  Google Scholar 

  53. Nakao N, Yoshimura A, Morita H, et al.: Combination treatment of angiotensin II receptor blocker and angiotensin converting enzyme inhibitor in non diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet 2003, 11:117–124.

    Article  Google Scholar 

  54. Mogensen C, Neldam S, Tikkanen I, et al.: Randomized controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microabluminuria (CALM) study. BMJ 2000, 321:1440–1444.

    Article  PubMed  CAS  Google Scholar 

  55. Jacobsen P, Andersen S, Jensen B, Parving H: Additive effect of ACE inhibitor and angiotensin II receptor blocker in type 1 diabetic patients with diabetic nephropathy. J Am Soc Nephrol 2003, 14:992–999.

    Article  PubMed  CAS  Google Scholar 

  56. Jacobsen P, Andersen S, Rossing K, et al.: Dual blockade of the renin angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy. Kidney Int 2003, 63:1874–1880.

    Article  PubMed  CAS  Google Scholar 

  57. Rossing K, Jacobsen P, Pietraszek L, Parving H: Renoprotective effects of adding angiotensin II receptor blocker to maximal recommended doses of ACE inhibitor in diabetic nephropathy: a randomized double-blind crossover trial. Diabetes Care 2003, 26:2268–2274.

    Article  PubMed  CAS  Google Scholar 

  58. Agarwal R: Add-on angiotensin receptor blockade with maximized ACE inhibition. Kidney Int 2001, 59:2282–2289.

    PubMed  CAS  Google Scholar 

  59. Epstein M: Aldosterone as a mediator of progressive renal disease: pathogenetic and clinical implications. Am J Kidney Dis 2001, 37:677–688.

    Article  PubMed  CAS  Google Scholar 

  60. Buckalew V, Martinez F, Altamirano J, et al.: The selective aldosterone blocker eplerenone is effective as monotherapy or adjunctive therapy in diabetic hypertensives with microalbuminuria. Paper presented at the American Diabetes Association 62nd Scientific Session. San Francisco, CA; 2002.

  61. Wrenger E, Muller R, Moesenthin M, et al.: Interaction of spironolactone with ACE inhibitors or angiotensin receptor blockers: analysis of 44 cases. BMJ 2003, 327:147–149.

    Article  PubMed  CAS  Google Scholar 

  62. Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial. The Diabetes Control and Complications (DCCT) [no authors listed]. Kidney Int 1995, 47:1703–1720.

  63. Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group: Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. JAMA 2002, 287:2563–2569.

    Article  Google Scholar 

  64. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Prospective Diabetes Study (UKPDS) Group [no authors listed]. Lancet 1998, 352:837–855.

  65. Hovind P, Rossing P, Tarnow L, et al.: Progression of diabetic nephropathy. Kidney Int 2001, 59:702–709.

    Article  PubMed  CAS  Google Scholar 

  66. Gall M, Hougaard P, Borch-Johnsen K, Parving H: Risk factors for development of incipient and overt diabetic nephropathy in patients with non-insulin dependent diabetes mellitus: prospective, observational study. BMJ 1997, 314:783–788.

    PubMed  CAS  Google Scholar 

  67. Ravid M, Neumann L, Lishner M: Plasma lipids and the progression of nephropathy in diabetes mellitus type 2: effect of ACE inhibitors. Kidney Int 1995, 47:907–910.

    Article  PubMed  CAS  Google Scholar 

  68. Fried L, Orchard T, Kasiske B: Effect of lipid reduction on the progression of renal disease: a meta-analysis. Kidney Int 2001, 59:260–269.

    Article  PubMed  CAS  Google Scholar 

  69. Orth S: Smoking and the kidney. J Am Soc Nephrol 2002, 13:1663–1672.

    Article  PubMed  CAS  Google Scholar 

  70. Chuahirun T, Wesson D: Cigarette smoking predicts faster progression of type 2 established diabetic nephropathy despite ACE inhibition. Am J Kidney Dis 2002, 39:376–382.

    PubMed  Google Scholar 

  71. Ritz E, Ogata H, Orth S: Smoking: a factor promoting onset and progression of diabetic nephropathy. Diabetes Metab 2000, 26:54–63.

    PubMed  CAS  Google Scholar 

  72. Levey A, Adler S, Caggiula A, et al.: Effects of dietary protein restriction on the progression of advanced renal disease in the Modification of Diet in Renal Disease Study. Am J Kidney Dis 1996, 27:652–663.

    PubMed  CAS  Google Scholar 

  73. Hansen H, Tauber-Lassen E, Jensen B, Parving H: Effect of dietary protein restriction on prognosis in patients with diabetic nephropathy. Kidney Int 2002, 62:220–228.

    Article  PubMed  Google Scholar 

  74. Gaede P, Vedel P, Parving H, Pedersen O: Intensified mulitfactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study. Lancet 1999, 353:617–622.

    Article  PubMed  CAS  Google Scholar 

  75. Gaede P, Vedel P, Larsen N, et al.: Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003, 348:383–393.

    Article  PubMed  Google Scholar 

  76. Remuzzi G, Ruggenenti P, Perico N: Clinical practice. Nephropathy in patients with type 2 diabetes. N Engl J Med 2002, 346:1145–1151. A review of diagnosis, progression, and treatment of type 2 diabetic nephropathy.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Nephrology and Dialysis, Ospedali Riuniti di Bergamo and Mario Negri Institute for Pharmacological Research, Negri Bergamo Laboratories, Via Gavazzeni, 11, 24125, Bergamo, Italy

    Giuseppe Remuzzi MD

Authors
  1. Ruth C. Campbell MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Piero Ruggenenti MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Giuseppe Remuzzi MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Campbell, R.C., Ruggenenti, P. & Remuzzi, G. Proteinuria in diabetic nephropathy: Treatment and evolution. Curr Diab Rep 3, 497–504 (2003). https://doi.org/10.1007/s11892-003-0014-0

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11892-003-0014-0

Keywords

Search

Navigation